Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 8 de 8
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Neuroscience ; 311: 474-83, 2015 Dec 17.
Artigo em Inglês | MEDLINE | ID: mdl-26545981

RESUMO

Exacerbated hippocampal activity has been associated to critical modifications of the intracellular signaling pathways. We have investigated rapid hippocampal adaptive responses induced by maximal electroshock seizure (MES). Here, we demonstrate that abnormal and exacerbated hippocampal activity induced by MES triggers specific and temporally distinct patterns of phosphorylation of extracellular signal-related kinase (ERK), mammalian target of rapamycin complex (mTORC) and Akt/glycogen synthase kinase-3 (Akt/GSK-3) pathways in the mouse hippocampus. While the ERK pathway is transiently activated, the mTORC1 cascade follows a rapid inhibition followed by a transient activation. This rebound of mTORC1 activity leads to the selective phosphorylation of p70S6K, which is accompanied by an enhanced phosphorylation of the ribosomal subunit S6. In contrast, the Akt/GSK-3 pathway is weakly altered. Finally, MES triggers a rapid upregulation of several plasticity-associated genes as a consequence exacerbated hippocampal activity. The results reported in the present study are reminiscent of the one observed in other models of generalized seizures, thus defining a common molecular footprint induced by intense and aberrant hippocampal activities.


Assuntos
Epilepsia Generalizada/enzimologia , MAP Quinases Reguladas por Sinal Extracelular/metabolismo , Quinase 3 da Glicogênio Sintase/metabolismo , Hipocampo/enzimologia , Complexos Multiproteicos/metabolismo , Convulsões/enzimologia , Serina-Treonina Quinases TOR/metabolismo , Animais , Western Blotting , Modelos Animais de Doenças , Eletroencefalografia , Eletrochoque , Epilepsia Generalizada/patologia , Imunofluorescência , Hipocampo/patologia , Alvo Mecanístico do Complexo 1 de Rapamicina , Camundongos Endogâmicos C57BL , Fosforilação , Proteínas Proto-Oncogênicas c-akt/metabolismo , Distribuição Aleatória , Convulsões/patologia , Transdução de Sinais
2.
Neurosci Lett ; 397(3): 234-9, 2006 Apr 24.
Artigo em Inglês | MEDLINE | ID: mdl-16406321

RESUMO

Succinic semialdehyde dehydrogenase (SSADH) is involved in the degradation of the inhibitory neurotransmitter GABA and about 50% of patients with SSADH deficiency suffer from seizures. The gene encoding SSADH (gene symbol: ALDH5A1) maps in proximity to susceptibility loci for juvenile myoclonic epilepsy (JME) and photosensitivity on chromosome 6p22. The present study tested whether variation of the ALDH5A1 gene confers susceptibility to common syndromes of idiopathic generalized epilepsy (IGE) and an abnormal photoparoxysmal response (PPR). Mutation screening of the ALDH5A1 coding sequence of 35IGE/PPR patients and four healthy control subjects identified 17 sequence variants, of which three resulted in an exchange of amino acids (H180Y, P182L, A237S). Association analysis was carried out for six single nucleotide polymorphisms (SNPs) and one trinucleotide repeat polymorphism (TNR, intron 1), covering the genomic ALDH5A1 sequence. The study sample comprised 566 unrelated German IGE patients, including 218 JME and 95 photosensitive IGE patients, 78 PPR probands without IGE, and 662 German population controls. None of the investigated ALDH5H1 polymorphisms showed evidence for an allelic or genotypic association with either IGE, JME, or PPR, when corrected for multiple tests. A tentative haplotypic association of the two-marker haplotype (rs1883415-TNR) covering the 5'-regulatory region in IGE patients (chi2=11.65, d.f.=3, P=0.009) warrants further replication studies. The present results do not provide evidence that any ALDH5A1 missense variant itself contributes a common and substantial susceptibility effect (RR>2) to IGE syndromes or an increased liability to visually-induced cortical synchronization.


Assuntos
Epilepsia Generalizada/genética , Epilepsia Reflexa/genética , Polimorfismo Genético , Succinato-Semialdeído Desidrogenase/genética , Epilepsia Generalizada/enzimologia , Epilepsia Reflexa/enzimologia , Predisposição Genética para Doença , Genótipo , Haplótipos , Humanos , Mutação de Sentido Incorreto , Polimorfismo de Nucleotídeo Único , Repetições de Trinucleotídeos
3.
Indian J Physiol Pharmacol ; 45(3): 296-304, 2001 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-11881568

RESUMO

There are several reports in literature implicating cholesterol metabolism in the pathogenesis of neuronal degenerations, oncogenesis, functional neuropsychiatric disorders and multiple sclerosis. Biosynthesis of cholesterol takes place by the isoprenoid pathway, which also produces digoxin, an inhibitor of membrane Na(+)-K+ ATPase. Inhibition of this enzyme results in intracellular Mg++ deficiency which can influence cholesterol metabolism. Digoxin also influences transport of tryptophan and tyrosine which are precursors of various neurotransmitters. Alterations in digoxin, membrane Na(+)-K+ ATPase and also in neurotransmitters have been reported in the disorders mentioned above. In view of this, serum lipid profile, activity of plasma HMG CoA reductase (the major rate limiting step in the isoprenoid pathway), RBC membrane Na(+)-K+ ATPase activity, serum Mg++ concentration, concentration of digoxin and concentration of serum neurotransmitters were studied in some neuropsychiatric disorders. The serum serotonin level was increased while that of serum dopamine and noradrenaline was reduced. Serum digoxin levels were high and RBC membrane sodium-potasium ATPase activity and serum magnesium were reduced. There was a reduction in HDL cholesterol and increase in plasma triglycerides (pattern similar to insulin resistance and syndrome X) in most of the disorders studied. The HMG CoA reductase activity was high, the serum total cholesterol was increased while RBC membrane cholesterol was reduced in most of the cases. The significance of increased digoxin with consequent inhibition of membrane Na(+)-K+ ATPase in relation to changes in cholesterol metabolism and insulin resistance type of dyslipidemia is discussed in this paper.


Assuntos
Membrana Eritrocítica/enzimologia , Hiperlipidemias/sangue , Resistência à Insulina/fisiologia , Transtornos Mentais/fisiopatologia , Doenças do Sistema Nervoso/fisiopatologia , ATPase Trocadora de Sódio-Potássio/sangue , Colesterol/sangue , Colesterol/metabolismo , Epilepsia Generalizada/enzimologia , Glioma/enzimologia , Humanos , Hidroximetilglutaril-CoA Redutases/sangue , Hiperlipidemias/enzimologia , Transtornos Mentais/sangue , Angina Microvascular/enzimologia , Esclerose Múltipla/enzimologia , Doenças do Sistema Nervoso/sangue , Doença de Parkinson/enzimologia , Esquizofrenia/enzimologia
4.
Epilepsia ; 41 Suppl 6: S195-9, 2000.
Artigo em Inglês | MEDLINE | ID: mdl-10999544

RESUMO

PURPOSE: To understand the role of nitric oxide (NO) in the regulation of seizures, we measured the extracellular levels of the NO metabolites nitrite and nitrate as indices of NO generation in the parietal cortex, hippocampus, and temporal cortex of EL mice. Furthermore, alterations of neuronal, endothelial, and inducible nitric oxide synthetase (nNOS, eNOS, and iNOS, respectively) were observed to correlate them with epileptogenesis. METHODS: EL mice of 20 weeks and 30 weeks of age (before and after the establishment of epileptogenesis, respectively) were used. Nitrite was quantified using the specific absorbancy of diazo dye. NOS isoenzymes (nNOS, iNOS, and eNOS) were also investigated in the hippocampus during development until mice were 30 weeks old. Samples (total protein, 8.33 to 8.43 microg) were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and identified by immunoblotting. RESULTS: EL mice that experienced repetitive seizures showed a remarkable increase in nitrite in the hippocampus at 30 weeks of age compared with EL mice that had no experience of seizures. nNOS and iNOS were major and minor components, respectively, and both increased in parallel with the development of epileptogenesis. eNOS was not detectable. CONCLUSIONS: Excess iNOS (and subsequent increase in harmful NO) and deficient eNOS (and subsequent decrease in NO identified as an endothelium-derived relaxing factor) may work together to form a focus complex.


Assuntos
Epilepsia Generalizada/fisiopatologia , Hipocampo/fisiopatologia , Plasticidade Neuronal , Óxido Nítrico/fisiologia , Lobo Parietal/fisiopatologia , Lobo Temporal/fisiopatologia , Animais , Colorimetria , Modelos Animais de Doenças , Epilepsia Generalizada/enzimologia , Espaço Extracelular/química , Espaço Extracelular/enzimologia , Hipocampo/química , Hipocampo/enzimologia , Immunoblotting , Isoenzimas/metabolismo , Camundongos , Camundongos Mutantes , Camundongos Mutantes Neurológicos , Óxido Nítrico/análise , Óxido Nítrico/biossíntese , Óxido Nítrico Sintase/metabolismo , Óxido Nítrico Sintase Tipo I , Óxido Nítrico Sintase Tipo II , Lobo Parietal/química , Lobo Parietal/enzimologia , Lobo Temporal/química , Lobo Temporal/enzimologia
5.
J Inherit Metab Dis ; 23(8): 819-25, 2000 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-11196107

RESUMO

Tyrosine hydroxylase (TH) deficiency is generally considered as a cause of the autosomal recessive form of dopa-responsive dystonia, also known as Segawa disease. Clinical hallmarks comprise parkinsonian and other extrapyramidal symptoms. Biochemically the defect leads to the defective synthesis of catecholamines, in particular dopamine. The diagnosis relies on a characteristic pattern of biogenic amine metabolites exclusively in the CSF and can be confirmed by establishing a mutation in the TH gene. Here we present a patient meeting all diagnostic criteria, including a new homozygous mutation (926T > C) with confirmed parental heterozygosity, extrapyramidal symptoms, but atypical other symptoms with periodic neurological episodes observed every 4 days and unresponsive to dopa treatment. The CSF biochemical abnormalities were severe. Uncharacteristically, a strongly abnormal urinary catecholamine metabolite pattern was also consistently observed. The atypical presentation of this patient shows that the clinical and metabolic phenotype of TH deficiency is more variable than formerly thought, and that the condition should no longer be considered as a treatable disorder per se.


Assuntos
Erros Inatos do Metabolismo dos Aminoácidos/tratamento farmacológico , Dopaminérgicos/uso terapêutico , Levodopa/uso terapêutico , Tirosina 3-Mono-Oxigenase/deficiência , Erros Inatos do Metabolismo dos Aminoácidos/enzimologia , Erros Inatos do Metabolismo dos Aminoácidos/genética , Erros Inatos do Metabolismo dos Aminoácidos/fisiopatologia , Pré-Escolar , Epilepsia Generalizada/tratamento farmacológico , Epilepsia Generalizada/enzimologia , Epilepsia Generalizada/genética , Humanos , Masculino , Hipotonia Muscular/tratamento farmacológico , Hipotonia Muscular/enzimologia , Hipotonia Muscular/genética , Falha de Tratamento , Tirosina 3-Mono-Oxigenase/genética
6.
Acta Neurol Scand ; 89(4): 237-41, 1994 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-7913793

RESUMO

Gamma glutamyl transferase (GGT) and alkaline phosphatase (ALP) may not be sensitive indicators of hepatocellular damage in patients taking anticonvulsant drugs as raised levels may only reflect enzyme induction. Aspartate aminotransferase (AST) is a specific, but relatively insensitive marker of liver damage and has a poor correlation with liver histology. Serum F protein is found in high concentration in the liver and levels are not influenced by enzyme induction. We measured serum F protein levels in patients taking carbamazepine (CBZ) and phenytoin (PHT) as monotherapy and in patients receiving multiple drugs. We compared the results with patients taking sodium valproate (VPA). Serum F protein levels were elevated in 6%, 22% and 13% of patients receiving CBZ, PHT and VPA, respectively. Raised GGT levels were reported for both the CBZ (26%) and PHT (78%) groups. Raised ALP levels were observed in 16%, 25% and 4% of the CBZ, PHT and VPA groups, respectively. Raised levels of serum F protein in the VPA group and the absence of any associated increases in either GGT or AST may further support the suggestion that serum F protein is an indicator of hepatocellular dysfunction associated with anticonvulsant therapy. However, further correlation with liver histology is required.


Assuntos
Anticonvulsivantes/efeitos adversos , Doença Hepática Induzida por Substâncias e Drogas/diagnóstico , Epilepsia/tratamento farmacológico , Isoantígenos/sangue , Adulto , Fosfatase Alcalina/sangue , Anticonvulsivantes/uso terapêutico , Aspartato Aminotransferases/sangue , Carbamazepina/efeitos adversos , Carbamazepina/uso terapêutico , Doença Hepática Induzida por Substâncias e Drogas/enzimologia , Quimioterapia Combinada , Epilepsias Parciais/tratamento farmacológico , Epilepsias Parciais/enzimologia , Epilepsia/enzimologia , Epilepsia Generalizada/tratamento farmacológico , Epilepsia Generalizada/enzimologia , Feminino , Humanos , Testes de Função Hepática , Masculino , Pessoa de Meia-Idade , Fenitoína/efeitos adversos , Fenitoína/uso terapêutico , Ácido Valproico/efeitos adversos , Ácido Valproico/uso terapêutico , gama-Glutamiltransferase/sangue
7.
Biull Eksp Biol Med ; 116(10): 362-4, 1993 Oct.
Artigo em Russo | MEDLINE | ID: mdl-8117950

RESUMO

Examination of 13 patients suffering from generalized epilepsy has shown about 20-25% decreases in the activity of superoxide dismutase (SOD) and glutathione peroxidase (GP) in red blood cells. Out of them 9 patients were treated with the antioxidant alpha-tocopherol (600 mg daily). Prior to alpha-tocopherol treatment all patients showed abnormal electroencephalographic (EEG) changes; 4 weeks later the effects of the antioxidant appeared as positive EEG changes, reduced frequency of epileptic seizures, increased SOD activity and patients' improved general state. Thus, the addition of the antioxidant to the multitherapy of epilepsy enhances antioxidative activity and therapeutical effects.


Assuntos
Anticonvulsivantes/uso terapêutico , Antioxidantes , Epilepsia Generalizada/tratamento farmacológico , Vitamina E/uso terapêutico , Adulto , Doença Crônica , Avaliação de Medicamentos , Quimioterapia Combinada , Eletroencefalografia/efeitos dos fármacos , Epilepsia Generalizada/enzimologia , Epilepsia Generalizada/fisiopatologia , Eritrócitos/efeitos dos fármacos , Eritrócitos/enzimologia , Humanos , Peroxidação de Lipídeos/efeitos dos fármacos , Masculino , Fatores de Tempo , Vitamina E/sangue
8.
Acta Neurol Scand ; 86(3): 275-9, 1992 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-1414247

RESUMO

Valproic acid induced coma is presented in an adult patient without a history of metabolic disease. Liver biopsy revealed a reduction in activity of carbamyl phosphate synthetase-I, an enzyme obligated for transformation of ammonia to urea in the urea cycle. After recovery CT scan follow-up showed marked cerebral atrophy which did not exist prior to the state of coma. Risk factors are discussed.


Assuntos
Carbamoil-Fosfato Sintase (Amônia)/deficiência , Coma/induzido quimicamente , Epilepsia Generalizada/tratamento farmacológico , Ácido Valproico/efeitos adversos , Adulto , Erros Inatos do Metabolismo dos Aminoácidos/diagnóstico , Erros Inatos do Metabolismo dos Aminoácidos/enzimologia , Amônia/sangue , Atrofia , Coma/enzimologia , Corpo Caloso/patologia , Relação Dose-Resposta a Droga , Quimioterapia Combinada , Epilepsia Generalizada/enzimologia , Feminino , Glutamina/líquido cefalorraquidiano , Humanos , Fenitoína/uso terapêutico , Tomografia Computadorizada por Raios X , Ácido Valproico/uso terapêutico
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...